JAK2 V617F Mouse Pathological Section Analysis: Histopathological Evaluation of Myeloproliferative N

JAK2 V617F mouse pathological section analysis delivers comprehensive histopathological characterization of myeloproliferative neoplasm (MPN) mouse models carrying the human JAK2 V617F transgenic or knock-in mutation. Through systematic H&E staining, special stains, and immunohistochemistry of bone marrow, spleen, liver, and other target organs, this service quantifies key disease hallmarks including myeloid hyperplasia, megakaryocyte clustering, extramedullary hematopoiesis, and progressive myelofibrosis to support disease phenotyping and preclinical drug evaluation.

Technical Overview

The Janus kinase 2 (JAK2) V617F mutation—a valine-to-phenylalanine substitution at codon 617 within the pseudokinase (JH2) domain—is the most common driver lesion in human Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). It is present in over 95% of polycythemia vera (PV) patients and approximately 50–60% of essential thrombocythemia (ET) and primary myelofibrosis (PMF) cases. The mutation abolishes autoinhibitory control of JAK2, causing constitutive activation of the JAK–STAT signaling pathway, uncontrolled myeloproliferation, splenomegaly, and progressive bone marrow fibrosis.

Mice engineered to express human JAK2 V617F, including transgenic (Vav1 promoter-driven) and knock-in conditional models, faithfully recapitulate the human MPN disease spectrum. These animals develop polycythemia, leukocytosis, thrombocytosis, marked splenomegaly, extramedullary hematopoiesis (EMH), and reticulin fibrosis, making them the standard platform for mechanistic research and preclinical testing of JAK inhibitors and anti-fibrotic therapies. Pathological section analysis provides the definitive morphological evidence needed to interpret disease severity and treatment response in these models.

Key Pathological Features of JAK2 V617F Mice

• Bone marrow: marked hypercellularity with panmyelosis, loss of adipose tissue, expanded and clustered atypical megakaryocytes, and progressive reticulin-to-collagen fibrosis with late-stage osteosclerosis
• Spleen: significant splenomegaly with disorganized red pulp architecture, expansion of megakaryocytic and myeloid populations, white pulp follicle compression or effacement, and active extramedullary hematopoiesis
• Liver: sinusoidal infiltration by hematopoietic precursors, portal tract EMH, and scattered megakaryocyte clusters
• Other organs: potential pulmonary thrombosis or hemorrhage, cardiac and renal extramedullary hematopoietic foci, and mesenteric lymph node myeloid expansion

Testing Samples

Bone Marrow

Femur, tibia, and vertebral column are the preferred specimens for marrow architecture evaluation. Bones are fixed in 10% neutral buffered formalin and decalcified in EDTA to preserve antigenicity for immunohistochemistry. Longitudinal femoral sections are recommended to maximize the evaluable marrow area and ensure consistent cellularity measurements across treatment groups.

Spleen and Liver

Spleen and liver are the principal organs affected by extramedullary hematopoiesis in JAK2 V617F mice. Spleen weight normalized to body weight should be recorded at necropsy as a complementary quantitative endpoint. Both organs are fixed, processed, and embedded using standardized orientations to guarantee comparable histological sections between animals.

Additional Organs

Lung, heart, kidney, brain, lymph nodes, and gastrointestinal tract may be collected to assess thrombotic complications, leukocyte infiltration, and systemic disease burden. Peripheral blood smears and femoral marrow cytospin preparations can be supplied alongside histological sections for cytomorphological correlation.

Sample Submission Requirements

• Fixation: 10% neutral buffered formalin or 4% paraformaldehyde at a 10–20 fold volume ratio for 24–48 hours
• Decalcification: 10% EDTA (pH 7.2–7.4) is strongly recommended when IHC is required; strong acid decalcification is faster but may destroy epitopes such as CD41 and CD42b
• Accepted formats: formalin-fixed tissues, paraffin blocks, pre-cut unstained slides (3–5 µm), or frozen specimens shipped on dry ice
• Documentation: strain, genotype, sex, age, treatment group, necropsy date, and organ weights should accompany every submission

Testing Items

Routine Histology (H&E)

Hematoxylin and eosin staining of all collected organs delivers a global assessment of disease phenotype, including marrow cellularity, splenic architecture disruption, hepatosplenic EMH, and secondary organ pathology.

Special Stains

• Gomori or Gordon–Sweets reticulin silver stain: the reference method for grading bone marrow reticulin fibrosis
• Masson's trichrome: detection of advanced collagen deposition and osteosclerosis
• Perls' Prussian blue: evaluation of marrow iron stores and hemosiderin-laden macrophages in spleen and liver

Immunohistochemistry Panel

• Megakaryocytic lineage: CD41, CD42b, von Willebrand factor
• Myeloid lineage: Ly6G, myeloperoxidase (MPO), CD11b
• Erythroid lineage: CD71, Ter119
• Macrophage and stromal markers: F4/80, CD68, alpha-SMA
• Lymphoid lineage: CD3 (T cells), B220 (B cells)
• Proliferation and apoptosis: Ki-67, cleaved caspase-3
• Fibrosis markers: collagen type I, collagen type III, fibronectin

Quantitative and Semi-Quantitative Endpoints

• Bone marrow cellularity percentage and megakaryocyte density (cells per high-power field)
• Megakaryocyte cluster score and nuclear atypia grading
• Reticulin fibrosis grade (MF-0 to MF-3) with blinded dual-pathologist scoring
• Splenic EMH score, white pulp-to-red pulp ratio, and follicle preservation index
• Digital image analysis of IHC positive area and integrated optical density using ImageJ, Aperio, or HALO platforms

Testing Methods

Tissue Processing and Sectioning

Fixed tissues are dehydrated through graded alcohols, cleared in xylene, and paraffin-embedded under standardized programs. Sections are cut at 3–5 µm thickness, mounted on charged glass slides, and baked to ensure adhesion. For decalcified bone, gentle EDTA treatment (7–14 days) is applied with daily monitoring to avoid over-decalcification.

Staining Protocols

H&E, reticulin, Masson's trichrome, and Prussian blue protocols are executed with validated control slides in every batch. Reticulin staining quality is confirmed using normal spleen or lymph node tissue as a positive control, ensuring fine fiber networks are reliably visualized for fibrosis grading.

Immunohistochemistry Workflow

Deparaffinized sections undergo heat-induced epitope retrieval (citrate or EDTA buffer, optimized per antibody), endogenous peroxidase blocking, serum protein blocking, primary antibody incubation, HRP-polymer secondary detection, DAB chromogen development, and hematoxylin counterstaining. Known positive mouse tissues are included in each run to validate staining performance.

Myelofibrosis Grading Criteria (Mouse-Adapted WHO Scale)

• MF-0: normal reticulin network with no fiber increase
• MF-1: loose network of increased reticulin fibers without intersections
• MF-2: diffuse and dense increase in reticulin fibers with extensive intersections, occasionally with focal collagen bundles
• MF-3: dense reticulin network with widespread intersections, coarse collagen bundles, and associated osteosclerosis

Quality Control and Reporting

All slides are scored in a blinded manner by experienced veterinary or hematopathologists. The final report includes gross necropsy observations, complete histomorphological descriptions by organ, semi-quantitative fibrosis and EMH scores, high-resolution annotated photomicrographs, and group-level statistical comparisons to support robust efficacy or phenotyping conclusions.

Applications

• Phenotypic characterization and validation of newly established JAK2 V617F transgenic, knock-in, or humanized mouse strains
• Preclinical efficacy evaluation of JAK inhibitors such as ruxolitinib, fedratinib, and pacritinib using objective fibrosis and EMH endpoints
• Development and testing of anti-fibrotic, anti-inflammatory, and stroma-targeted therapies
• Mechanistic studies of clonal evolution, malignant transformation, the megakaryocyte–TGF-beta fibrosis axis, and MPN-associated inflammation
• Longitudinal disease progression studies correlating histopathology with hematology, flow cytometry, and molecular biomarkers
• Supporting histopathology data packages for IND-enabling studies and translational publications

FAQ

Why is pathological section analysis essential for JAK2 V617F mouse studies?

Hematological parameters such as blood counts confirm the MPN phenotype but cannot quantify marrow fibrosis, megakaryocyte atypia, or extramedullary hematopoiesis. Histopathology provides direct, spatially resolved morphological evidence of disease burden and treatment response, which is often the primary or key secondary endpoint in preclinical MPN studies.

Which organs should be collected at necropsy?

The minimum recommended panel includes femur or tibia (bone marrow), spleen, and liver. Adding lung, heart, kidney, and lymph nodes provides a more complete assessment of thrombotic complications and systemic disease infiltration.

How is bone marrow fibrosis graded in mice?

Reticulin-stained decalcified bone sections are scored using a mouse-adapted four-tier WHO scale (MF-0 to MF-3) by blinded pathologists. Masson's trichrome is added to confirm collagen fibrosis in advanced MF-2 and MF-3 cases, and digital image analysis can supplement semi-quantitative scores with objective fiber area measurements.

Should EDTA or acid decalcification be used?

EDTA decalcification is strongly recommended whenever immunohistochemistry is planned, because acid decalcification frequently destroys lineage antigens such as CD41, CD42b, and Ly6G. If rapid processing is required, mild formic acid methods may be used for H&E-only panels with the client's prior approval.

How many animals are recommended per group?

For efficacy studies, a minimum of 5–8 mice per group with both sexes represented is recommended to achieve statistical power for fibrosis scores and cellularity measurements. Including disease-positive and wild-type negative control groups in every study is essential for valid interpretation.

What is the typical turnaround time?

Standard processing, H&E, special stains, and a routine IHC panel are typically completed within 10–15 working days after sample receipt, depending on decalcification duration, panel size, and the complexity of quantitative image analysis requirements.